Cryo-Cell International (CCEL) Stock Analysis & AI Equity Report

Medical - Care Facilities USD Explore free reports

Cryo-Cell International (CCEL) overview

Cryo-Cell International (CCEL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 31.6m and operating profit of USD 0.5m; the year-end share price was 4.30 USD and market capitalisation was USD 34.6m. Cryo-Cell International is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Cryo-Cell International's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -18.6mFY 2025
Share price4.30 USDFY 2025 year end
RevenueUSD 31.6mFY 2025
Operating profitUSD 0.5mFY 2025
Net earningsUSD -2.4mFY 2025
Market capitalisationUSD 34.6mFY 2025 year end

About Cryo-Cell International

Cryo-Cell International provides cellular processing and cryogenic storage services, primarily preserving umbilical cord blood and tissue stem cells for family use. It also manufactures the PrepaCyte CB system, a technology used to process cord blood stem cells, and processes and stores cord blood for public use. Its stored specimens are maintained for the benefit of newborns and potentially other family members.

Generate the Cryo-Cell International report

Cryo-Cell International is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Cryo-Cell International and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Cryo-Cell International

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.